Revelation Biosciences, Inc. (REVBW)

US — Healthcare Sector
Peers: REVB  SABSW  SRZNW  JSPRW  ISPOW 

Automate Your Wheel Strategy on REVBW

With Tiblio's Option Bot, you can configure your own wheel strategy including REVBW - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol REVBW
  • Rev/Share 0.0
  • Book/Share 2.9658
  • PB 0.2982
  • Debt/Equity 0.0
  • CurrentRatio 3.6052
  • ROIC -2.8354

 

  • MktCap 852381.0
  • FreeCF/Share -23.9667
  • PFCF -0.0366
  • PE -0.0596
  • Debt/Assets 0.0
  • DivYield 0
  • ROE -0.0122

 

  • Rating B-
  • Score 2
  • Recommendation Sell
  • P/E Score 1
  • DCF Score 5
  • P/B Score 5
  • D/E Score 1

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
No ratings available.

News

About Revelation Biosciences, Inc. (REVBW)

  • IPO Date
  • Website https://www.revbiosciences.com
  • Industry Biotechnology
  • CEO Mr. James M. Rolke
  • Employees 8

Revelation Biosciences, Inc., a clinical stage biopharmaceutical company, focuses on the development of immunologic-based therapeutics and diagnostics for the prevention and treatment of disease. The company's lead therapeutic candidate is REVTx-99, an intranasal immunomodulator to prevent or treat infections caused by various respiratory viruses, such as SARS-CoV-2 comprising its variants, influenza A and B, parainfluenza, rhinovirus, and RSV, as well as is being developed for other indications comprising allergic rhinitis and chronic nasal congestion. It also develops REVTx-200, an intranasal immunomodulator adjunct to be used in combination with an intramuscular vaccination for immunity; and REVDx-501, a rapid home use diagnostic to detect respiratory viral infection. The company was founded in 2019 and is based in New York, New York.